In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.